亞洲 中樞神經
中樞神經藥：從癲癇、失眠到思覺失調與帕金森氏症。
8追蹤資產
7已核准
這個賽道在做什麼
中樞神經藥物必須穿過血腦屏障，作用在難以量測的腦部迴路，所以開發慢、失敗率高。日本藥廠在這個領域累積很深，美國常用的幾個抗精神病、抗癲癇、失眠與帕金森氏症藥物都源自日本；韓國 SK Biopharmaceuticals 則靠自己把癲癇新藥做到美國核准。中國正陸續推出新的抗憂鬱藥與神經科候選藥。
階段分布
已核准7 7
第二期1 1
國家分布
日本6 6
韓國1 1
中國1 1
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lurasidone (SM-13496; Latuda) | lurasidone | Sumitomo Pharma Co., Ltd. (formerly Dainippon Sumitomo Pharma) | Japan | Dopamine D2; serotonin 5-HT2A / 5-HT7 / 5-HT1A | D2 / 5-HT2A / 5-HT7 antagonist and 5-HT1A partial agonist | Approved — US (2010-10) | Schizophrenia; bipolar depression (Japan approval 2020-03) | NCT00868959 | Angelini (selected European territories); Sumitomo group companies elsewhere | 2017-11-21 | Not disclosed | Not disclosed | Japan approved Latuda for schizophrenia and bipolar depression | 2020-03-25 | 1 2 3 4 | 2020-03-25 |
| 2 | Perampanel (E2007; Fycompa) | perampanel | Eisai Co., Ltd. | Japan | AMPA-type glutamate receptor | Selective non-competitive AMPA receptor antagonist | Approved — US (2012-10) | Partial-onset seizures (US approval); pediatric epilepsy (selected investigational study) | NCT04015141 | Catalyst Pharmaceuticals (US commercial rights acquisition) | 2022-12-20 | USD 160m | Not disclosed | Pediatric adjunctive epilepsy study registry updated; active, not recruiting | 2026-07-10 | 1 2 3 4 | 2026-07-10 |
| 3 | Brexpiprazole (OPC-34712; Rexulti) | brexpiprazole | Otsuka Pharmaceutical Co., Ltd. | Japan | Dopamine D2; serotonin 5-HT1A / 5-HT2A | D2 / 5-HT1A partial agonism and 5-HT2A antagonism; clinical mechanism not fully established | Approved — US (2015-07) | Schizophrenia; adjunctive MDD treatment; agitation associated with dementia due to Alzheimer disease (US approval 2023-05) | NCT01838681 | Lundbeck (co-development/co-commercialization in agreed territories) | 2011-11-11 | Not disclosed (asset-specific; USD 200m portfolio upfront) | Not disclosed (asset-specific; up to USD 1.8bn portfolio agreement) | US approval of additional indication for agitation associated with dementia due to Alzheimer disease announced | 2023-05-11 | 1 2 3 4 5 | 2023-05-11 |
| 4 | Istradefylline (KW-6002; Nourianz / Nouriast) | istradefylline | Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin) | Japan | Adenosine A2A receptor | Selective adenosine A2A receptor antagonist | Approved — US (2019-08) | Adjunct to levodopa/carbidopa in adults with Parkinson disease experiencing OFF episodes | NCT02610231 | None reported | — | — | — | Long-term Parkinson disease study registry updated; completed | 2024-04-25 | 1 2 3 | 2024-04-25 |
| 5 | Cenobamate (YKP3089; Xcopri / Ontozry) | cenobamate | SK Biopharmaceuticals Co., Ltd. (with SK Life Science) | South Korea | Voltage-gated sodium channels; GABAA ion channel | Proposed sodium-current inhibition and GABAA positive allosteric modulation; precise therapeutic mechanism unknown | Approved — US (2019-11) | Partial-onset seizures in adults (US approved); pediatric partial-onset seizures (investigational) | NCT05067634 | Angelini Pharma / Arvelle (41 European countries; US via SK Life Science) | 2019 (original licence; takeover announced 2021-01-04) | USD 100m (2019 European licence) | Not disclosed (USD 430m milestone obligations separately reported) | Pediatric Phase 3 registry updated; study completed | 2026-10-16 | 1 2 3 4 | 2026-10-16 |
| 6 | Lemborexant (E2006; Dayvigo) | lemborexant | Eisai Co., Ltd. | Japan | Orexin OX1R and OX2R | Competitive dual orexin receptor antagonist | Approved — US (2019-12) | Adult insomnia characterized by sleep-onset and/or sleep-maintenance difficulty | NCT01463098 | None reported | — | — | — | China approval of Dayvigo for adult insomnia announced | 2025-05-27 | 1 2 3 4 | 2025-05-27 |
| 7 | Toludesvenlafaxine (LY03005; ansofaxine; Ruoxinlin) | toludesvenlafaxine | Luye Pharma Group Ltd. | China | Serotonin, norepinephrine and dopamine transporters | Serotonin-norepinephrine-dopamine reuptake inhibitor (company characterization) | Approved — China (2022-11) | Major depressive disorder (approved); generalized anxiety disorder (China NDA accepted) | NCT04853407 | None reported | — | — | — | China CDE accepted NDA for generalized anxiety disorder indication | 2026-01-08 | 1 2 3 4 5 | 2026-01-08 |
| 8 | Matsupexole (KDT-3594) | matsupexole | Kissei Pharmaceutical Co., Ltd. | Japan | Dopamine receptors | Oral non-ergot dopamine receptor agonist | Phase 2 — Japan (2021-05) | Parkinson disease; early PD and advanced PD with levodopa (investigational) | jRCT2031210089 | jRCT2051240199 | AffaMed (China, Taiwan, Hong Kong, Macao and six Southeast Asian countries) | 2020-10-09 | Not disclosed | Not disclosed | July 2026 company pipeline lists matsupexole at Phase 2 | 2026-07 | 1 2 3 4 5 6 7 | 2026-07 |